Key Biologics, has completed its merger with Astarte Biologics to provide research- and clinical-grade human immune cells, blood products, and related services to the biopharmaceutical industry. In conjunction with the merger the new entity also received an investment from Ampersand Capital Partners to continue expanding the company in the rapidly evolving cell and gene therapy markets. Memphis-based…